Three-year outcome of photodynamic therapy combined with VEGF inhibitor for pachychoroid neovasculopathy
Three-year outcome of photodynamic therapy combined with VEGF inhibitor for pachychoroid neovasculopathy
复制标题
DOI：
10.1007/s00417-024-06499-6
复制
发表时间：
2024-05-09
影响因子：
2.7
通讯作者：
Obata，Ryo
中科院分区：
文献类型：
--
作者：
Nomura，Yoko;Aoki，Shuichiro;Obata，Ryo
Backgroundphotodynamic therapy（PDT）联合vascular endothelial growth factor（VEGF）抑制剂治疗pachychoroid neovasculopathy（PNV.MethodsThis study is a retrospective，observational case series.我们回顾性研究了未经治疗的PNV病例（22例，22只眼，平均年龄71.0岁），他们接受PDT治疗联合VEGF抑制剂，随后采用pro re nata方案进行额外治疗。检查视力、治疗次数和复发时间。此外，中心凹脉络膜厚度和脉络膜血管指数（CVI）进行了评估，在13的22例患者随访SpectralisOCT从baseline. Results 15（68%）例息肉在基线。基线时LogMAR视力平均为0.24 ± 0.20（范围：-0.079至0.82），1年、2年和3年后显著改善（p= 0. 001）。004、0.0003、0.002）。14例患者（64%）复发，平均复发时间为1.8 ± 0.9年。中心凹脉络膜厚度在1年后显著降低（平均从326 μm降至263 μm），并保持不变，直至3年（255 μm）。CVI在1年后也有所下降（平均从0.62降至0.61），并保持不变，直到3年后（0.60）。结论我们检查了PDT联合VEGF抑制剂治疗未经治疗的PNV的3年疗程。3年后视力提高，中心凹脉络膜厚度和CVI降低。
BackgroundLong-term results of photodynamic therapy (PDT) combined with vascular endothelial growth factor (VEGF) inhibitors for pachychoroid neovasculopathy (PNV) are not yet clear.MethodsThis study is a retrospective, observational case series. We retrospectively examined untreated PNV cases (22 cases, 22 eyes, mean age of 71.0 years) who underwent PDT therapy in combination with VEGF inhibitors followed by additional treatments with pro re nata protocol. Visual acuity, number of treatments, and time to recurrence were examined. In addition, foveal choroidal thickness and choroidal vascularity index (CVI) were evaluated in 13 of 22 patients who were followed up with SpectralisOCTRfrom baseline.ResultsFifteen (68%) cases had polyps at baseline. LogMAR visual acuity averaged 0.24 ± 0.20 (range, − 0.079 to 0.82) at baseline and significantly improved after 1, 2, and 3 years (p= 0. 004, 0.0003, 0.002, respectively). Fourteen patients (64%) recurred, with an average time to recurrence of 1.8 ± 0.9 years. Foveal choroidal thickness decreased significantly after 1 year (average from 326 μm to 263 μm) and remained unchanged up to 3 years (255 μm). CVI also decreased after 1 year (average from 0.62 to 0.61) and remained unchanged until 3 years later (0.60).ConclusionsWe examined the 3-year course of PDT in combination with the VEGF inhibitor for untreated PNV. Visual acuity was improved, foveal choroidal thickness and CVI were decreased after 3 years.